Report Publication Announcement • Mar 22, 2017
Report Publication Announcement
Open in ViewerOpens in native device viewer
Press release, March 22, 2017
Lund, Sweden - Alligator Bioscience AB (Nasdaq Stockholm; ATORX) today announces that that the Swedish version of Annual Report for 2016 now is available at the company's website, the English version will be posted next week. www.alligatorbioscience.com
Per Norlén, CEO Telephone: + 46 46 286 42 80 (switchboard) E-mail: [email protected]
Rein Piir, VP Investor Relations Telephone: +46 708 537292 E-mail: [email protected]
Per-Olof Schrewelius, CFO Telephone: +46 46 286 42 85 E-mail: [email protected]
The information in the press release is such that Alligator Bioscience AB is required to disclose pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, at 16.00 CET on 22 March, 2017.
Alligator is a biotechnology company that develops innovative immune activating antibody drugs for tumor-directed immunotherapy. The Company has a pipeline of lead clinical and preclinical product candidates: ADC-1013, ATOR-1015 and ATOR-1016 as well as various research candidates. In August 2015, ADC-1013 was out-licensed to Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for further development and commercialization. The Company's shares are listed on Nasdaq Stockholm under the ticker "ATORX". The Company is headquartered in Lund, Sweden, and has approximately 40 employees. For more information, please visit www.alligatorbioscience.com.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.